JNJ
Johnson & JohnsonNYSEHealthcare$243.04-0.44%OpenMarket Cap: $585.70B
As of 2026-04-06
Valuation
P/E (TTM)
21.85
PEG
0.24
P/B
7.24
P/S
6.22
EV/EBITDA
15.41
DCF Value
$316.55
FCF Yield
3.4%
Div Yield
2.1%
Margins & Returns
Gross Margin
72.8%
Operating Margin
27.2%
Net Margin
28.5%
ROE
33.8%
ROA
26.8%
ROIC
13.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $24.56B | 86.4% | $5.39B | $5.12B | $2.10 | $1.30 |
| FY 2025 | $94.19B | 72.8% | $25.60B | $26.80B | $11.03 | $5.14 |
| Q3 2025 | $23.99B | 69.6% | $7.10B | $5.15B | $2.12 | $1.30 |
| Q2 2025 | $23.74B | 67.9% | $6.81B | $5.54B | $2.29 | $1.30 |
| Q1 2025 | $21.89B | 66.4% | $6.30B | $11.00B | $4.54 | $1.24 |
| Q4 2024 | $22.52B | 68.3% | $3.84B | $3.43B | $1.41 | $1.24 |
| FY 2024 | $88.82B | 69.1% | $22.15B | $14.07B | $5.79 | $4.91 |
| Q3 2024 | $22.47B | 69.0% | $5.28B | $2.69B | $1.11 | $1.24 |
| Q2 2024 | $22.45B | 69.4% | $6.66B | $4.69B | $1.93 | $1.24 |
| Q1 2024 | $21.38B | 69.6% | $6.27B | $3.25B | $1.34 | $1.19 |
| Q4 2023 | $21.39B | 68.2% | $4.61B | $4.05B | $1.67 | $1.19 |
| FY 2023 | $85.16B | 68.8% | $23.41B | $35.15B | $13.72 | $4.70 |